Evidence map›Paper›PMID 26927611›Full record

ArticleExpert opinion on therapeutic targets2016

Targeting constitutively active androgen receptor splice variants in castration resistant prostate cancer.

M T Schweizer, S R Plymate

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Expert opinion on therapeutic targets, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Intracrine androgen biosynthesis and drug resistance.Cancer drug resistance (Alhambra, Calif.) · 2020
    Review
  5. Article
  6. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

2 authors.

M T Schweizera Department of Medicine, Division of Medical Oncology , University of Washington , Seattle , WA , USA.
S R Plymatec Department of Medicine and GRECC VAPSHCE , University of Washington , Seattle , WA , USA.

Funding

TRANSCRIPTOME AND PROTEOME STRATIFICATION OF PROSTATE ADENOCARCINOMA PHENOTYPESP50CA097186 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI John Kyung Lee · 2002 to 2026
$58.1M
Tumor and Circulating Markers as Links Between Obesity and Lethal Prostate CanceP50CA090381 · NCI · DANA-FARBER CANCER INSTITUTE · PI LODA, MASSIMO · 2002 to 2017
$36.2M
Steroid Metabolism in Castration-Resistant Prostate CancerP01CA163227 · NCI · BETH ISRAEL DEACONESS MEDICAL CENTER · PI Henry W. Long · 2013 to 2026
$25.0M
Mechanisms for the Transition to Castrate Resistant Prostate CancerI01BX000585 · VA · VA PUGET SOUND HEALTHCARE SYSTEM · PI PLYMATE, STEPHEN R. · 2009 to 2013
–
Targeting the Metabolome in Androgen Receptor-driven Castration-resistant Prostate CancerI01BX003324 · VA · VA PUGET SOUND HEALTHCARE SYSTEM · PI PLYMATE, STEPHEN R. · 2016 to 2024
–
BLRD VA I01 BX000585BLRD VA I01 BX003324NCI NIH HHS P01 CA163227NCI NIH HHS P50 CA090381NCI NIH HHS P50 CA097186
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

OrchiectomyAntineoplastic AgentsBiomarkers, TumorDrug Delivery SystemsGene Expression Regulation, NeoplasticHumansMaleMolecular Targeted TherapyProstatic NeoplasmsProtein IsoformsReceptors, AndrogenAntineoplastic AgentsBiomarkers, TumorProtein IsoformsReceptors, AndrogenAndrogen receptordrug resistanceprostate cancersplice variants

Identifiers

PMID26927611
PMCPMC4975933

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.